New vVARDIS funding backs world Curodont growth

ZUG, Switzerland: Swiss producer vVARDIS has raised an extra US$50 million (€43 million^*) in investment from world healthcare investor OrbiMed, bringing the whole capital secured to US$85 million. The financing will improve the corporate’s endured growth of its minimally invasive product line and business operations international.

The brand new capital injection follows OrbiMed’s preliminary US$35 million funding in February, which used to be geared toward accelerating the rollout of Curodont in the USA. That capital supported the scaling of medical and gross sales groups, the improvement of distribution infrastructure and deeper engagement with dental pros throughout key markets.

Curodont is a non-invasive remedy designed to arrest and remineralise preliminary carious lesions. Its biomimetic method interacts with calcium and phosphate ions in saliva to advertise tooth regeneration on the website of demineralisation. As a needle- and drill-free selection to traditional restorative approaches, it helps minimally invasive dentistry through protecting herbal enamel construction and lowering operative time.

Drs Haleh and Golnar Abivardi, founders and co-CEOs of vVARDIS, mentioned: “We’re overjoyed to extend our partnership with OrbiMed as we input this subsequent segment of enlargement. This extra investment, mixed with OrbiMed’s strategic experience, will boost up our skill to serve dental pros and sufferers globally. As dentists, we’re extremely joyful to carry ahead a drill-free remedy for early decay that guarantees to lift the usual of handle sufferers around the globe.”

Matthew Rizzo, basic spouse at OrbiMed, commented: “After our preliminary funding, we’ve observed first-hand the momentum vVARDIS is construction within the dental marketplace with its Curodont merchandise. We got here in at a pivotal second—simply because the product started gaining actual traction—and the corporate’s fast growth and the marketplace’s reaction have since bolstered our trust within the important alternatives forward. That’s why we’re excited to deepen our dedication and extend our funding to improve vVARDIS in its subsequent segment of enlargement.”

In keeping with vVARDIS, it’s the fastest-growing dental producer in its class. In a fresh press free up, the corporate additionally said that, since January 2024, multiple million tooth had been handled with Curodont in the USA and that almost 10% of dental practices within the nation at the moment are providing the remedy, which has been utilized in greater than 400,000 sufferers.

Editorial observe:

^* Calculated at the OANDA platform for 15 July 2025.